Joseph L Lasky III MD

Pediatric Hematology & Oncology•Las Vegas, NV

Medical Director, Pediatric Hematology/Oncology, Cure 4 The Kids Foundation

Join to View Full Profile

1 Breakthrough WayLas Vegas, NV 89135
Phone+1 702-732-1493
Fax+1 702-732-1080

Summary

Dr. Joseph Lasky is a pediatric hematologist/oncologist in Las Vegas, NV. He received his medical degree from University of Illinois College of Medicine and has been in practice 17 years. He is experienced in sickle-cell anemia, pediatric sarcomas, leukemia, pediatric bone marrow transplantation, and pediatric hematopoietic stem cell transplantation.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 2003 - 2006
University of ChicagoResidency, Pediatrics, 2000 - 2003
University of Illinois College of MedicineClass of 2000

Certifications & Licensure

CA State Medical License 2003 - 2026
NV State Medical License 2017 - 2025
IL State Medical License 2000 - 2003
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma Start of enrollment: 2005 Jan 01
Completed
Phase 1
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
ACTIVE_NOT_RECRUITING
PHASE3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
ACTIVE_NOT_RECRUITING
PHASE3
Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A Start of enrollment: 2013 Mar 01
Unknown status
Phase 3
INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections Start of enrollment: 2017 May 11
Recruiting
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

10 citations
Recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in patients with mild and moderate von Willebrand disease in the USA (VWDMin): a pha...
Margaret V Ragni, Scott D Rothenberger, Robert Feldman, Danielle Nance, Andrew D Leavitt
The Lancet. Haematology. 2023-08-01
1 citations
Case Report: Blinatumomab as upfront consolidation and maintenance therapy in a pediatric patient with high-risk B-cell acute lymphoblastic leukemia.
Sumit Gupta, Jessica Casey, Joseph Lasky
Frontiers in Oncology. 2023-01-01
2 citations
Pediatric Patients With Sickle Cell Disease at a Public Hospital: Nutrition, Compliance and Early Experience With L-Glutamine Therapy.
Moran Gotesman, Guy Elgar, Laura Hernandez Santiago, Abigail Alvarez, Youngju Pak
In Vivo. 2022-06-23

Journal Articles

A Phase 3 Trial of L-glutamine in Sickle Cell Disease
Rita Bellevue, Joseph L Lasky, Elliott P Vichinsky, Lewis L Hsu, Sharada Sarnaik, Lynne D Neumayr, Yutaka Niihara, Sophie Lanzkron, Ifeyinwa Osunkwo, Lance Sieger, Edu..., The New England Journal of Medicine

Abstracts/Posters

Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial
Joseph Lasky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Consistent Benefit of L-Glutamine Observed across Patients with Low, Medium, and High Number of Crises Reported in the Year Prior to Screening -- Analysis from the Pha...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Introducing Vegas Inc’s 2021 Top DoctorsAugust 26th, 2021